Risk for Nonscarring Hair Loss Increased in Association With GLP-1 Receptor Agonist Use
WEDNESDAY, Feb. 18, 2026 — The risk for nonscarring hair loss (NSHL) is increased in association with glucagon-like peptide-1 receptor agonist (GLP-1 RA) use, according to a study published online Feb. 9 in the Journal of the American Academy of…
Lilly’s Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results
🤝 Lilly’s Zepbound plus Taltz combo: The company said the drugs, when taken together, helped 27.1% of patients with plaque psoriasis and obesity (or who were overweight) achieve full skin clearance …
GLP-1s Bringing Back Scurvy? Achondroplasia Drug Win; Intermittent Fasting Flop
(MedPage Today) — The meteoric rise of GLP-1 drugs for weight loss has raised concerns about potential malnutrition and even the comeback of scurvy. (The Hill)
An $80-per-month produce prescription subsidy failed to improve cardiometabolic health…
Taking the next shot: GLP-1 research and the new era of weight loss
Soaring in popularity, GLP-1 medications—from weekly injections to newly available pills—are rapidly reshaping how Americans think about weight loss. In fact, a recent poll finds 1 in 8 adults are now taking medications like Ozempic or Wegovy for weight loss or chronic conditions, and use is expected to keep rising.
STAT+: Pharmalittle: We’re reading about China’s homegrown GLP-1 drugs, a puzzling FDA rejection, and more
The FDA rejected a Disc Medicine therapy for a rare blood disorder, the first experimental drug to go through a new program to fast-track drug reviews
STAT+: As China’s drug industry races ahead, its GLP-1 race is accelerating too
To understand what China’s fast-developing drug industry might mean for global pharmaceutical companies, look no further than the market for GLP-1 drugs.
Bariatric surgery programs face upheaval amid growing GLP-1 use for weight loss
At Roxborough Memorial Hospital in Philadelphia, surgeon Piotr Krecioch has his hands full launching a program offering surgical interventions to treat obesity. One in three Philadelphians are living with obesity, putting them at higher risk of chronic conditions like diabetes and heart disease, but these days fewer are seeking the bariatric surgical procedures long considered a leading medical treatment for the condition.
Despite Side Effects, People Continue Taking Ozempic for Weight Loss
People who lose weight with GLP-1 drugs are likely to continue using the medication despite the side effects. Image Credit: geckophotos/Getty Images
A recent study found that many people using GLP-1 drugs for weight loss choose to continue the medication despite unpleasant side effects.
The researchers found that in addition to weight loss, perceived reductions in appetite and cravings were the strongest predictors of satisfaction and intention to continue treatment with Ozempic.
Will Ozempic-style patches help you lose weight? Two experts explain
Could a simple patch, inspired by the weight-loss drug Ozempic, really help you shed excess kilos without the pain and effort of an injection?
Obesity rates are rising, despite GLP-1s. What does it mean?
By 2030, nearly half of all American adults will have obesity, according to research published in the New England Journal of Medicine. In every single state, researchers expect at least 35% of adults to have a body mass index of 30 or higher, the threshold that defines obesity. That prediction may come as a shock, as weight loss medications like Wegovy and Zepbound become more popular and more affordable.